Valuation: Eris Lifesciences Limited

Market Cap 152B 1.6B 1.43B 1.32B 1.2B 2.24B 2.28B 15.89B 6.29B 79.63B 6.01B 5.88B 251B P/E 2027 *
25.1x
P/E 2028 * 19x
Enterprise Value 170B 1.79B 1.6B 1.48B 1.34B 2.51B 2.55B 17.79B 7.04B 89.11B 6.72B 6.58B 281B EV / Sales 2027 *
4.83x
EV / Sales 2028 * 4.06x
Free-Float
30.16%
Yield 2027 *
0.66%
Yield 2028 * 0.81%
1 day-2.29%
1 week-4.27%
Current month-8.09%
1 month-14.05%
3 months-21.78%
6 months-20.24%
Current year-27.24%
1 week 1,087.9
Extreme 1087.9
1,149.9
1 month 1,087.9
Extreme 1087.9
1,293
Current year 1,087.9
Extreme 1087.9
1,563
1 year 1,087.9
Extreme 1087.9
1,740
3 years 804
Extreme 804
1,910
5 years 551.3
Extreme 551.3
1,910
10 years 321
Extreme 321
1,910
Manager TitleAgeSince
Chief Executive Officer 52 2007-01-26
Director of Finance/CFO 46 2016-09-27
Chief Tech/Sci/R&D Officer - 2010-04-30
Director TitleAgeSince
Chairman 52 2007-01-26
Director/Board Member 54 2007-01-26
Director/Board Member 46 2018-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-2.29%-4.27%-30.78%+32.59% 1.6B
-2.54%+1.31%+54.27%+114.96% 1,135B
-1.42%+3.23%+38.56%+74.44% 635B
+0.16%+0.08%+25.29%+95.23% 505B
-0.31%+3.09%+44.14%+64.80% 378B
-1.34%-0.47%+66.04%+41.00% 358B
-0.68%+2.65%+22.98%+50.39% 295B
-1.20%+3.04%+2.33%+22.86% 266B
-1.79%+1.57%+50.56%+59.08% 237B
-0.73%-0.10%+29.02%+99.67% 193B
Average -1.21%+1.52%+30.24%+65.50% 400.53B
Weighted average by Cap. -1.35%+2.66%+41.00%+79.73%

Financials

2027 *2028 *
Net sales 35.21B 371M 331M 306M 277M 519M 527M 3.68B 1.46B 18.45B 1.39B 1.36B 58.16B 40.28B 424M 379M 350M 317M 594M 603M 4.21B 1.67B 21.11B 1.59B 1.56B 66.54B
Net income 6.01B 63.31M 56.54M 52.23M 47.33M 88.55M 90.02M 629M 249M 3.15B 238M 233M 9.93B 7.94B 83.64M 74.69M 69M 62.53M 117M 119M 830M 329M 4.16B 314M 307M 13.12B
Net Debt 18.09B 191M 170M 157M 142M 267M 271M 1.89B 749M 9.48B 715M 700M 29.88B 11.5B 121M 108M 99.96M 90.58M 169M 172M 1.2B 476M 6.03B 455M 445M 19B
Projected Income Statement - Annual - Eris Lifesciences Limited
Logo Eris Lifesciences Limited
Eris Lifesciences Limited is an India-based pharmaceutical company. The Company is engaged in the manufacture and marketing of pharmaceutical products. The Company has a presence in major therapies like oral anti-diabetes, insulins, cardiovascular, vitamins/minerals and dermatology. Its flagship therapies include oral anti-diabetes, cardiovascular disease (CVD), and vitamins, minerals and nutrients (VMN). Its emerging therapies consist of dermatology, insulins, women’s health, central nervous system (CNS), oncology, and nephrology. Its portfolio of brands includes Glimisave, Eritel, LNBloc, Olmin, Crevast, Atorsave, Gluxit, Renerve, Zomelis, Cosvate, Tayo, Cyblex, Remylin, Tendia, Rabonik, Ginkocer, Psorid, Raricap, Serlift, and Onabet, among others. Its patient care initiatives (PCI) platform provides various healthcare solutions to its patients. The Company has a manufacturing plant located in Guwahati, Assam.
Employees
2,758
Date Price Change Volume
26-10-23 ₹1,095.50 -2.29% 37,943
26-10-22 ₹1,121.20 -1.33% 29,717
26-10-21 ₹1,136.30 +1.42% 84,960
26-10-19 ₹1,120.40 -2.10% 28,791
26-10-16 ₹1,144.40 -0.38% 80,705
Trader
Investor
Global
Quality
ESG MSCI
BB
MarketScreener Ratings - Eris Lifesciences Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
1,095.50INR
Average target price
1,632.20INR
Spread / Average Target
+48.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Eris Lifesciences Limited
  1. Stock Market
  2. Stocks
  3. ERIS Stock